Hui Min Jin

Dr. Hui Min Jin


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Atherosclerosis
Verified
Journal Article
Closed access
XYXiu Hong Yang
Xiu Hong Yang
BZBao Long Zhang
Bao Long Zhang
YCYun Cheng
Yun Cheng
SFShun Kun Fu
Shun Kun Fu
HJHui Min Jin
Hui Min Jin

1 March 2015 in Journal of Public Health
Verified
Journal Article
Closed access
PDF file
YPYu Pan
Yu Pan
XYXiu Hong Yang
Xiu Hong Yang
JHJiang Ping He
Jiang Ping He
YGYan Hong Gu
Yan Hong Gu
XZXiao Li Zhan
Xiao Li Zhan
HJHui Min Jin
Hui Min Jin

18 March 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
QTQian Ming Tu
Qian Ming Tu
HJHui Min Jin
Hui Min Jin
XYXiu Hong Yang
Xiu Hong Yang
Numerous studies have shown that dyslipidemia increases the risk of atherosclerotic cardiovascular disease (ASCVD) and significantly impacts the occurrence and progression of diabetic kidney disease (DKD). Early interventions for lipid metabolism disorders in DKD may improve renal function. This article reviews the clinical characteristics of dyslipidemia, mechanisms of lipid-induced renal injury, and advances in lipid-lowering therapy in DKD. We searched PubMed, Web of Science, and EMBASE to identify relevant articles, using keywords such as “diabetic kidney disease”, “diabetic nephropathy”, “diabetes”, “dyslipidemia”, “kidney”, “cardiovascular disease”, and “lipid therapy”. High triglyceride (TG) and low high-density lipoprotein (HDL) are associated with increased risks of albuminuria and estimated glomerular filtration rate (eGFR) decline. Abnormal lipid metabolism may damage glomerular podocytes and renal tubular epithelial cells via ectopic lipid deposition, eventually impairing glomerular filtration function and increasing urinary albumin excretion. Lipid-lowering therapies can ameliorate lipid accumulation, downregulate inflammatory mediator expressions, and alleviate renal fibrosis. Fibrate and statin applications exhibit beneficial effects, reducing albuminuria and slowing eGFR decline in early DKD. However, the long-term effects of statins and fibrates on renal outcomes remain controversial. Pro-protein convertase subtilisin/kexin 9 (PCSK9)-targeted interventions have minimal side effects on the kidneys and seem effective in reducing inflammation and improving renal impairment compared with statins and fibrates. In addition, LDL apheresis (LDL-A) and double filtration plasmapheresis (DFPP) are promising clinical applications in diabetic patients with severe hypercholesterolemia or lipid-lowering drug intolerance.

1 December 2018 in Archives of Psychiatric Nursing
Verified
Journal Article
Closed access
HZHong Jun Zeng
Hong Jun Zeng
GZGui Ying Zhou
Gui Ying Zhou
HYHui Hong Yan
Hui Hong Yan
XYXiu Hong Yang
Xiu Hong Yang
HJHui Min Jin
Hui Min Jin

1 November 2018 in Sleep Medicine
Verified
Journal Article
Closed access
XYXiu Hong Yang
Xiu Hong Yang
BZBao Long Zhang
Bao Long Zhang
YGYan Hong Gu
Yan Hong Gu
XZXiao Li Zhan
Xiao Li Zhan
LGLi Li Guo
Li Li Guo
HJHui Min Jin
Hui Min Jin

27 August 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XYXiu Hong Yang
Xiu Hong Yang
BZBao Long Zhang
Bao Long Zhang
XZXiao Meng Zhang
Xiao Meng Zhang
JTJin Dong Tong
Jin Dong Tong
YGYan Hong Gu
Yan Hong Gu
HJHui Min Jin
Hui Min Jin
To explore whether epigallocatechin-3-gallate (EGCG) improves renal damage in diabetic db/db mice and high-glucose- (HG-) induced injury in HK-2 cells by regulating the level of Klotho gene promoter methylation. Western blotting was used to detect the protein expression levels of DNA methyltransferase 1 (DNMT1), DNMT3a, DNMT3b, transforming growth factor-β1 (TGF-β1), α-smooth muscle actin (α-SMA), and Klotho. The methylation level of the Klotho gene promoter was detected by pyrosequencing. Chromatin immunoprecipitation was used to detect the binding of the Klotho gene promoter to DNMT1 and DNMT3a. The expression of oxidative stress markers (reactive oxygen species (ROS), superoxide dismutase (SOD), malondialdehyde (MDA), catalase (CAT), and 8-hydroxy-2′-deoxyguanosine (8-OHdG)) and inflammatory cytokines (interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α)) in kidney homogenates was also measured using ELISA. Klotho and DNMT3b protein expression was upregulated, while DNMT1, DNMT3a, TGF-β1, and α-SMA protein expression was downregulated after EGCG treatment. EGCG treatment also reduced the methylation level of the Klotho gene promoter as well as the binding of DNMT3a to the Klotho gene promoter. In addition, EGCG treatment significantly decreased the levels of ROS, MDA, 8-OHdG, IL-1β, IL-6, and TNF-α and increased the levels of CAT and SOD. Under HG conditions, EGCG regulated Klotho gene promoter methylation via DNMT3a and decreased the methylation level of the Klotho gene promoter, thereby upregulating the expression of the Klotho protein to exert its protective effect.